Panion & Bf Biotech Inc. (TPE:1760)
Taiwan
· Delayed Price · Currency is TWD 68.40
-1.40 (-2.01%)
Apr 29, 2026, 1:30 PM CST
Panion & Bf Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,063 | 2,030 | 1,882 | 2,399 | 1,901 | Upgrade
|
| Revenue Growth (YoY) | 1.66% | 7.85% | -21.54% | 26.16% | 21.20% | Upgrade
|
| Cost of Revenue | 946.54 | 959.37 | 907.48 | 1,080 | 989.07 | Upgrade
|
| Gross Profit | 1,117 | 1,070 | 974.4 | 1,319 | 912.14 | Upgrade
|
| Selling, General & Admin | 612.69 | 618.22 | 601.58 | 656.06 | 587 | Upgrade
|
| Research & Development | 195.46 | 236.88 | 217.04 | 248.5 | 157.71 | Upgrade
|
| Other Operating Expenses | - | 9.84 | - | - | - | Upgrade
|
| Operating Expenses | 809 | 864.61 | 817.57 | 904.63 | 746.8 | Upgrade
|
| Operating Income | 307.85 | 205.67 | 156.83 | 413.96 | 165.34 | Upgrade
|
| Interest Expense | -14.34 | -15.02 | -11.36 | -7.59 | -14.68 | Upgrade
|
| Interest & Investment Income | 4.19 | 10.46 | 11.19 | 4.77 | 7.02 | Upgrade
|
| Earnings From Equity Investments | 2.65 | -8.44 | -14.02 | -8.18 | -12.17 | Upgrade
|
| Currency Exchange Gain (Loss) | -10.8 | 11.95 | -2.97 | -0.32 | -3.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.28 | 10.77 | 21.33 | 17.55 | 33.84 | Upgrade
|
| EBT Excluding Unusual Items | 293.82 | 215.39 | 161.01 | 420.2 | 176.28 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.24 | 1.46 | 7.5 | -93.68 | 6.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.13 | -0.1 | -0.38 | 6.28 | -0.44 | Upgrade
|
| Other Unusual Items | 0.11 | 0.69 | 0.58 | 0.61 | 0.08 | Upgrade
|
| Pretax Income | 294.04 | 217.44 | 168.71 | 333.41 | 182.65 | Upgrade
|
| Income Tax Expense | 103.87 | 92.91 | 91.49 | 151.06 | 78.25 | Upgrade
|
| Net Income | 190.17 | 124.52 | 77.22 | 182.35 | 104.4 | Upgrade
|
| Net Income to Common | 190.17 | 124.52 | 77.22 | 182.35 | 104.4 | Upgrade
|
| Net Income Growth | 52.72% | 61.26% | -57.65% | 74.66% | 274.19% | Upgrade
|
| Shares Outstanding (Basic) | 86 | 86 | 86 | 86 | 79 | Upgrade
|
| Shares Outstanding (Diluted) | 86 | 86 | 86 | 86 | 79 | Upgrade
|
| Shares Change (YoY) | 0.11% | 0.01% | -0.04% | 8.32% | 3.18% | Upgrade
|
| EPS (Basic) | 2.22 | 1.45 | 0.90 | 2.13 | 1.32 | Upgrade
|
| EPS (Diluted) | 2.21 | 1.45 | 0.90 | 2.12 | 1.32 | Upgrade
|
| EPS Growth | 52.41% | 61.11% | -57.55% | 60.78% | 266.26% | Upgrade
|
| Free Cash Flow | 161.23 | 165.49 | -3.81 | 291.23 | 231.22 | Upgrade
|
| Free Cash Flow Per Share | 1.88 | 1.93 | -0.04 | 3.39 | 2.92 | Upgrade
|
| Dividend Per Share | 2.000 | 1.800 | 1.500 | 2.000 | 1.500 | Upgrade
|
| Dividend Growth | 11.11% | 20.00% | -25.00% | 33.33% | 114.29% | Upgrade
|
| Gross Margin | 54.13% | 52.73% | 51.78% | 54.97% | 47.98% | Upgrade
|
| Operating Margin | 14.92% | 10.13% | 8.33% | 17.26% | 8.70% | Upgrade
|
| Profit Margin | 9.22% | 6.13% | 4.10% | 7.60% | 5.49% | Upgrade
|
| Free Cash Flow Margin | 7.81% | 8.15% | -0.20% | 12.14% | 12.16% | Upgrade
|
| EBITDA | 422.29 | 341.73 | 298.19 | 546.26 | 275.7 | Upgrade
|
| EBITDA Margin | 20.47% | 16.84% | 15.85% | 22.77% | 14.50% | Upgrade
|
| D&A For EBITDA | 114.45 | 136.06 | 141.36 | 132.29 | 110.36 | Upgrade
|
| EBIT | 307.85 | 205.67 | 156.83 | 413.96 | 165.34 | Upgrade
|
| EBIT Margin | 14.92% | 10.13% | 8.33% | 17.26% | 8.70% | Upgrade
|
| Effective Tax Rate | 35.32% | 42.73% | 54.23% | 45.31% | 42.84% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.